{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.79","value":"16.67"},{"groupId":"OG001","spread":"10.00","value":"19.47"},{"groupId":"OG002","spread":"8.80","value":"18.29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"63"}],"units":"Participants"}],"description":"Serial blood samples were collected for bortezomib Cmax analysis. Results are reported in ng/mL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 20 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG000","title":"Arm A - Panobinostat (20 mg, TIW)"},{"description":"Participants received 20 mg panobinostat BIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG001","title":"Arm B - Panobinostat (20 mg, BIW)"},{"description":"Participants received 10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG002","title":"Arm C - Panobinostat (10 mg, TIW)"}],"paramType":"MEAN","populationDescription":"Pharmacokinetics Analysis Set (PAS): all participants with at least 1 evaluable pharmacokinetics concentration of bortezomib after dosing on Day 1. Here, 'Overall Number of Participants Analyzed' refers to the number of evaluable participants analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Pre-dose, up to 8 hours post dose)","title":"Cmax: Bortezomib","type":"SECONDARY","unitOfMeasure":"ng/mL"}